Document:

<PAGE>
                                                                  Exhibit 10.13

                           FINAL SETTLEMENT AGREEMENT
                           --------------------------

     FINAL SETTLEMENT AGREEMENT is entered into and made as of March 26, 2003
(the "Settlement Effective Date"), by and between

     SUMITOMO PHARMACEUTICALS CO. LTD., a company organized, resident and
existing under the laws of Japan, with its principal place of business at 2-8,
Doshomachi 2-chome, Chuo-ku, Osaka, Japan (hereinafter "SUMITOMO") and

     IDENIX B.V. (formerly known as Novirio B.V.), a company organized, resident
and existing under the laws of The Netherlands, with its principal place of
business at Locatellikade 1, 1076 AZ Amsterdam, The Netherlands (together with
its Affiliates, hereinafter "IDENIX").

                                    RECITALS
                                    --------

     1.   IDENIX and SUMITOMO are parties to a Development Agreement dated June
29, 2001 relating to the development and registration of the product referred to
therein as the LdT Drug Product for indications related to the treatment of
hepatitis B (the "Development Agreement").

     2.   IDENIX and SUMITOMO are also parties to a Commercialization Agreement
dated as of September 17, 2001 relating to the commercialization of LdT Drug
Product for indications related to the treatment of hepatitis B (the
"Commercialization Agreement, together with the Development Agreement are
hereinafter referred to as the "Original Agreements").

     3.   Pursuant to the Original Agreements, IDENIX has granted to SUMITOMO
the exclusive right to commercialize LdT Drug Product in the countries of Japan,
the People's Republic of China (including Hong Kong and Macau)("PRC"), the
Republic of Korea ("Korea") and the Republic of China ("Taiwan")(collectively,
the "Territory.").

     4.   IDENIX and SUMITOMO amended the Original Agreements by the First
Amendment Agreement as of October 8th, 2002 ("Amendment"), providing for return
to IDENIX of rights to develop and commercialize LdT Drug Product in the PRC,
Korea and Taiwan (collectively, the "Northeast Asia").

     5.   SUMITOMO has then expressed its intention to terminate both of the
Original Agreements and the Amendment and return to IDENIX all rights inuring to
SUMITOMO incident to its execution and performance of the Original Agreements to
the date of this Final Settlement Agreement.

     6.   SUMITOMO proposes to transfer to IDENIX any and all rights, property
or interests relating to the subject matter of the Original Agreements and the
Amendment which arose incident to SUMITOMO's performance of the Original
Agreements and the Amendment and render such additional assistance to be
rendered in Japan to IDENIX and/or its affiliates or licensees as may reasonably
be required to continue and expedite further development of LdT Drug Product in
the Territory building upon work performed by the parties to date.

<PAGE>

     7.   Duly considering SUMITOMO's abovementioned intention to return of the
LdT Drug Product rights to IDENIX and/or its designee, IDENIX is willing to
accept acquisition of such rights and termination both of the Original
Agreements and the Amendment, on the terms and conditions hereinafter set forth.

     In consideration of the Recitals and the mutual covenants set forth in this
Final Settlement Agreement and the Original Agreements and the Amendment, the
Parties hereby agree as follows:

                                   ARTICLE I
                                   ---------

            TERMINATION OF SUMITOMO BENEFITS FROM ORIGINAL AGREEMENTS

1.1  TERMINATION OF ALL SUMITOMO RIGHTS AND BENEFITS UNDER THE ORIGINAL
     AGREEMENTS.

Except as otherwise set forth herein, upon the Settlement Effective Date, any
and all rights, benefits, obligation and liability accruing to SUMITOMO under
the Original Agreements and the Amendment shall be terminated and fully
extinguished, including but not limited to any benefits or rights to future
payments that may have accrued incident to the First Amendment of the Original
Agreements and the Amendment and reassign and vest any such rights in IDENIX as
of the date of this Final Settlement Agreement. SUMITOMO hereby waives, releases
and terminates any rights it may now or in future have incident to the Original
Agreement and the Amendment to any additional drug candidates discovered by
IDENIX.

1.2  SUMITOMO RELIEF FROM FURTHER DEVELOPMENT OBLIGATIONS

SUMITOMO hereby surrenders and/or reverts to IDENIX any rights, benefits,
property or interests, and IDENIX hereby releases SUMITOMO from any obligation
or liability, for the further development of the LdT Drug Product. IDENIX hereby
waives irrevocably any claims against SUMITOMO arising from the development of
the LdT Drug Product based upon facts in existence as of the Settlement
Effective Date. Beyond the amount of potential future payments set forth in
Article II, IDENIX further releases SUMITOMO from any additional liability for
any claim arising from any failure to support to be rendered by SUMITOMO to
IDENIX pursuant to Article III below.

1.3  TERMINATION OF IDENIX OBLIGATIONS AND LIABILITIES.

Other than the obligations to make repayments set forth in Article II below,
IDENIX shall have no obligations, liabilities nor owe any reimbursement of
expenses or costs that may or have been incurred by SUMITOMO incident to
Original Agreements nor shall IDENIX nor any of its licensees or affiliates owe
any costs or fees which SUMITOMO may incur in the future in the course of
returning all rights SUMITOMO may have as of the Settlement Effective Date with
respect to the LdT Drug Product dealt with in the Original Agreements to IDENIX,
including but not limited to filings with governmental agencies, inventions,
data, plans, patents or other matters developed obtained or provided by SUMITOMO
incident to the performance of the Original Agreements or rendering support and
assistance to IDENIX or its affiliates or licensees

                                       2
<PAGE>

to facilitate their further development of the LdT Drug Products incident to the
terms of this Final Settlement Agreement.

                                   ARTICLE II
                                   ----------

                                   REPAYMENTS

2.1  In compensation for return of the LdT Drug Product rights to IDENIX and
     provided that SUMITOMO has performed and continues to perform its transfer
     and support obligations as set forth in Article III below, IDENIX shall pay
     to SUMITOMO:

     2.1.1  Two Million US Dollars (US$2,000,000.00) with forty five (45) days
            of the Settlement Effective Date

     2.1.2  Three Million US Dollars (US$3,000,000.00) within the earlier of (i)
            six months after the Settlement Effective Date or (ii) thirty days
            after the date a sublicense agreement is executed with a Third Party
            for LdT Drug Product rights to Japan

2.2  In addition to the repayment stipulated in Section 2.1 above, IDENIX shall
     pay to SUMITOMO Five Million US Dollars (US$5,000,000.00) if and when the
     first commercial sale of LdT Drug Product in Japan for Hepatitis B
     infection occurs.

2.3  IDENIX shall use all reasonable and legal efforts to reduce tax withholding
     on repayments made to SUMITOMO hereunder. Notwithstanding such efforts, if
     IDENIX concludes that tax withholdings under the laws of any country are
     required with respect to payments to SUMITOMO, IDENIX may withhold the
     required amount and pay it to the appropriate governmental authority. In
     such a case, IDENIX shall promptly provide SUMITOMO with original receipts
     or other evidence reasonably desirable and sufficient to allow SUMITOMO to
     document such tax withholdings adequately for purposes of claiming foreign
     tax credits and similar benefits.

2.4  All payments hereunder shall be made in United States dollars by electronic
     bank transfer to such bank account as SUMITOMO designates.

                                  ARTICLE III
                                  -----------

                             SUPPORT AND ASSISTANCE

3.1  After the Settlement Effective Date, SUMITOMO shall:

     1.   subject to the necessary consent of the relevant party or regulatory
          bodies, return to IDENIX or its affiliates or licensees all rights in,
          and transfer to IDENIX all physical embodiments of, all intellectual
          or industrial property, know how and materials obtained or developed
          by SUMITOMO on or prior to the Settlement Effective Date incident to
          the performance of the Original Agreements, including but not limited
          to the Jointly-owned Developments (as defined in the Development
          Agreement), any government filings, any development plans, any data or
          materials developed in the preparation or execution of pre-clinical or

                                       3
<PAGE>

          clinical plans and all correspondence written and kept in SUMITOMO's
          file, files or reference materials prepared or developed in the course
          of the performance of the Original Agreements with respect to the LdT
          Drug Product, provided that SUMITOMO may retain one file copy of such
          materials for SUMITOMO's records, all of such documents, materials,
          regulatory filings and contracts with third parties as the parties now
          believe shall be required for transfer are specified in the Exhibit A
          attached hereto. SUMITOMO shall make reasonable efforts to obtain such
          consent of the relevant party or regulatory bodies as necessary to
          perform the transfer of the documents or other materials pursuant to
          this Article 3.1 above;

     2.   attend such meetings with governmental agencies in Japan and to
          execute such documents to be filed with governmental agencies in Japan
          which are necessary to be attended or executed by SUMITOMO in order to
          facilitate the rapid and effective transfer of any filing or work
          products heretofore done or held by SUMITOMO relating to LdT or other
          potential product rights specified in the Original Agreement, provided
          that scheduling of such meetings shall be discussed by SUMITOMO and
          IDENIX well in advance; and

     3.   execute such transfers of filings, patent applications or other
          governmental filings relating to the matters obtained or developed by
          SUMITOMO, if any, in the performance of the Original Agreements as
          necessary IDENIX or its affiliates or licensees in its endeavors to
          promote development and commercialization of LdT in the Territory.

3.2  IDENIX shall submit a receipt to SUMITOMO with respect to the physical
     embodiments of, all intellectual or industrial property, know how and
     materials transferred pursuant to Article 3.1 above when IDENIX receives
     any of them.

3.3  SUMITOMO represents that, as of the Settlement Effective Date, to the best
     of its knowledge and belief SUMITOMO is unaware of the existence of any
     violation of or deviation from the applicable laws and regulation regarding
     the development of LdT Drug Product by SUMITOMO. EXCEPT AS EXPRESSLY
     PROVIDED IN THIS ARTICLE 3.3, SUMITOMO EXTENDS NO WARRANTIES, EXPRESS OR
     IMPLIED, INCLUDING WARRANTIES OF PERFORMANCE, MERCHANTABILITY, INTEGRITY,
     CORRECTNESS AND FITNESS FOR PARTICULAR USE OR PURPOSE WITH RESPECT TO ANY
     DOCUMENTS OR OTHER MATERIALS. IDENIX ASSUMES ANY AND ALL RISKS AND
     LIABILITIES RESULTING FROM OR IN CONNECTION WITH THE USE OF THE DOCUMENTS
     OR OTHER MATERIALS.

3.4  SUMITOMO shall not act intentionally to damage the reputation of the LdT
     Drug Product with governmental agencies in Japan as is justified by the
     data generated by the LdT Drug Product.

                                    ARTICLE V
                                    ---------

                                       4
<PAGE>

                       SUPERIORITY OF SETTLEMENT AGREEMENT

The terms and conditions of this Final Settlement Agreement supercede and
control any terms and conditions in the Original Agreements and any Amendments
thereto, contrary or inconsistent with the terms and the conditions of this
Final Settlement Agreement.

                                   ARTICLE VI
                                   ----------

                           CONFIDENTIALITY AND NON-USE
                           ---------------------------

For the avoidance of any doubt, the Article VI. I of the Development Agreement
shall remains in effective for five (5) years from the Settlement Effective Date
against SUMITOMO with respect to the Confidential Information (as defined by the
Development Agreement) of IDENIX and any information obtained through the
clinical trial on LdT conducted by SUMITOMO.

                                   ARTICLE VII
                                   -----------

                                  MISCELLANEOUS

This Final Settlement Agreement shall be construed and enforced in accordance
with the laws of the State of Delaware, without giving effect to the conflict of
law provisions thereof.

     IN WITNESS WHEREOF, the Parties have executed this FINAL SETTLEMENT
AGREEMENT effective as of the date first set forth above.

                                           IDENIX B.V.

Witness: /s/ illegible                     By:   /s/ Jean-Pierre Sommadossi
        --------------------------            --------------------------------
                                              Jean-Pierre Sommadossi, Ph.D.
                                              Authorized Signature

                                           Place of Signing: /s/ Boston, MA
                                                            ---------------

                                           Date of Signing:  May 6, 2003
                                                           -------------

                                           SUMITOMO PHARMACEUTICALS CO., LTD.

Witness: /s/ Hiroshi Noguchi               By:   /s/ Masaaki Yokotsuka
        --------------------------            -------------------------------
                                              Masaaki Yokotsuka
                                              President

                                           Place of Signing: /s/ Tokyo, Japan
                                                            --------------------
                                           Date of Signing:  /s/ March 26, 2003
                                                           ---------------------

                                       5
<PAGE>

                                    EXHIBIT A

                     LIST OF AVAILABLE SUMITOMO INFORMATION
                     --------------------------------------

1.   RECORD OF ALLOCATION OF CLINICAL STUDY RELATED OPERATIONS
2.   INVESTIGATOR'S BROCHURE AND THE RELATED RECORDS
3.   PROTOCOL FOR CLINICAL TRIAL, RECORD OF ITS PREPARATION AND REVISION
4.   RECORD OF SELECTION OF COMMITTEE MEMBERS, CONTRACT RESEARCH ORGANIZATION,
     AND CONTRACT LABORATORIES (MAY REQUIRE CONSENT FOR DISCLOSURE)
5.   RECORD OF SELECTION OF CLINICAL TRIAL SITES AND A PRINCIPAL INVESTIGATOR
6.   RECORD OF REQUESTS OF CLINICAL TRIAL AND AGREEMENT FOR CLINICAL TRIAL
7.   RECORD OF MANUFACTURING INVESTIGATIONAL DRUG
8.   RECORD OF ALLOCATION OF INVESTIGATIONAL DRUG
9.   RECORD OF PHARMACEUTICAL PREPARATION TESTS
10.  RECORD OF DISTRIBUTION OF INVESTIGATIONAL DRUG
11.  RECORD OF RETRIEVAL OF INVESTIGATIONAL DRUG
12.  RECORD OF DISPOSAL OF INVESTIGATIONAL DRUG
13.  RECORD OF MONITORING
14.  SAFETY INFORMATION
15.  CASE REPORT AND THE RELATED RECORD
16.  RECORD OF INSPECTION OF ORIGINAL DOCUMENTS
17.  RECORD OF DATA MANAGEMENT
18.  RECORD OF KEY OPEN
19.  RECORD OF STATISTICAL ANALYSIS
20.  RECORD OF CONTRACT LABORATORIES
21.  CLINICAL STUDY REPORT (INCOMPLETE)
22.  RECORD OF AUDIT (UNDER REVIEW)
23.  NOTIFICATION OF CLINICAL TRIALS
24.  CONSULTATION WITH THE REGULATORY AUTHORITIES (DOCUMENTS FOR CONSULTATION
     AND CONSULTATION MINUTES)
25.  RECORDS OF ARRANGEMENT OF INVESTIGATIONAL DRUG
26.  RECORDS OF CLINICAL TRIAL APPLICATION IN CHINA

                                       6<PAGE>

                                                                   EXHIBIT 10.14

          Confidential Materials omitted and filed separately with the
         Securities and Exchange Commission. Asterisks denote omissions.

CNRS No. 751272/03

                                                        UM2 N degrees: 03/CR/009

                              RESTATED AND AMENDED

                              COOPERATIVE AGREEMENT

                                     BETWEEN

IDENIX SARL (FORMERLY KNOWN AS NOVIRIO SARL),
Private Corporation whose headquarters is located at Immeuble "La Vigie" 170 rue
Leon Blum, 34000 Montpellier, trade registered in Montpellier under the No.
B419909148 in the corporate and trade register, REPRESENTED BY MR. JEAN-MARC
ALLAIRE, VICE PRESIDENT EUROPE,

acting in its name and in the name and on behalf of Idenix Pharmaceuticals,
Inc., (formerly known as Novirio Pharmaceuticals Limited), hereafter
collectively named IDENIX, represented by Mr. Jean-Pierre Sommadossi, Chairman
of the Board of Directors,

AND

LE CENTRE NATIONAL DE IN RECHERCHE SCIENTIFIQUE,
Public Institution for scientific and technological research, whose headquarters
is 3 rue Michel-Ange 75794, Paris, Cedex 16, France SIREN N degrees 180 089 013
; APE Code 732Z, REPRESENTED BY ITS DIRECTOR GENERAL, MADAME GENEVIEVE BERGER,
who grants a power of attorney to Mr. Michel RETOURNA, CNRS Regional Delegate
for the Languedoc-Roussillon Delegation to execute this Agreement,

                           hereafter named the "CNRS",

AND

L'UNIVERSITE MONTPELLIER II,
Public Institution with a cultural and professional vocation, located 2 place
Eugene Bataillon 34095 Montpellier Cedex 5, SIRET N degrees 193 410 883 00014,
APE Code 803Z REPRESENTED BY ITS PRESIDENT, MR. JACQUES BONNAFE,

                            hereafter named "UM II",

                                                                          Page 1

<PAGE>

Both the CNRS and the UM II, hereafter referred to as the Organization, acting
in their names and in the name and on behalf of the "Laboratoire de Chimie
Organique Biomoculeculaire de Synthese", UMR5625 of the CNRS, directed by Mr.
Gilles Gosselin,

                    hereafter referred to as the "LABORATORY"

The CNRS, the UM II and Idenix being collectively designated hereafter in this
document as "THE PARTIES",

AND

NOVARTIS PHARMA AG, a company registered under the laws of Switzerland, whose
headquarters are located Lichstrasse 35, 4056 Basel, Switzerland, REPRESENTED BY
MR. SUBBANU SAXENA, HEAD, BUSINESS DEVELOPMENT AND LICENSING-PRIMARY CARE, AND
BY MR. ROBERT PELZER, GENERAL COUNSEL

                       hereafter referred to as "NOVARTIS"

which is entering into this Agreement for limited purposes and is undertaking
only certain rights and obligations as provided in this Agreement.

Novartis is acting on its own behalf and on behalf of its Affiliates, with the
exception of IDENIX, hereafter referred to as "NOVARTIS AFFILIATES"; such
Affiliates being defined as any corporation, company, partnership, joint venture
and/or firm that controls, is controlled by, or is under common control with
Novartis. For purposes of this definition of "Affiliate", "control" shall mean
(a) in the case of corporate entities, direct or indirect ownership of at least
fifty percent (50%) of the stock or shares having the right to vote for the
election of directors, and (b) in the case of non-corporate entities, direct or
indirect ownership of at least fifty percent (50%) of the equity interest with
the power to direct the management and policies of such non-corporate entities.

WHEREAS, the Parties have entered into a Cooperative Laboratory Agreement
effective as of January 1, 1999 (CNRS Agreement # 751272/00), which has been
amended by supplemental Agreements dated May 17, 2001 (First Amendment #
751272/01) and April 11, 2002 (Second Amendment # 751272/02).

WHEREAS, the Parties have agreed to make additional amendments to the
Cooperative Laboratory Agreement.

WHEREAS, in addition, Idenix, certain stockholders of Idenix and Novartis have
entered into an agreement on March 21, 2003, under which Novartis has agreed to
acquire a majority equity interest in Idenix. Idenix and Novartis have further
agreed that they will enter into agreements to jointly develop and commercialize
Idenix's core antiviral drug candidates. In particular, Idenix and Novartis
expect to enter into an agreement relating to the development and
commercialization of certain products (hereafter the "DEVELOPMENT, LICENSE AND
COMMERCIALIZATION AGREEMENT") and an agreement relating to the manufacture and
supply of drug candidates and product (hereinafter the "Master Manufacturing and
Supply Agreement").

                                                                          Page 2

<PAGE>

As part of this cooperation, the Parties and Novartis have agreed that, after
execution and during the term of the Development, License and Commercialization
Agreement, Novartis and Novartis Affiliates would be expressly permitted to
exercise certain rights of Idenix under the Agreement as expressly provided in
this Agreement.

WHEREAS, the Parties now wish to amend and restate the Cooperative Laboratory
Agreement to incorporate the amendments agreed among them, and in particular,
the addition of Novartis as a limited party to the Agreement.

NOW, THEREFORE, the Parties agree to amend and restate the Cooperative
Laboratory Agreement as follows:

THE FOLLOWING IS AGREED TO:

ARTICLE 1. PURPOSE OF THE AGREEMENT

Together the Parties plan to conduct a research program and to allocate
material, financial, and human resources to it. The entity formed by the
research program and the means allocated to it is named the "cooperative
Laboratory of research on nucleosidic substances", hereafter designated as the
COOPERATIVE LABORATORY.

The purpose of this agreement is to define the operating methods of the
COOPERATIVE LABORATORY. It consists of a group of organizations whose aim is to
achieve a common goal, and does not imply in any way the creation of a legal
entity. It excludes the "affectio societatis" (intention to co-operate in a
partnership and right to supervise its administration*) and any other direct or
indirect association with any corporation in any form whatsoever. Specifically,
with regard to third parties, each of the Parties will act in its own name and
on its own behalf.

[*EDITOR'S NOTE: F.H.S. Bridge: The Council of Europe French-English Legal
Dictionary]

In addition, the purpose of this Agreement is to define the rights granted to
Novartis and Novartis Affiliates under this Agreement, as expressly and
exclusively provided in Articles 7 and 12 of this Agreement, and in Articles 1,
2, 3 and 4.3 of Annex 3 to this Agreement, and subject to the limitations set
forth in Article 12 of this Agreement.

ARTICLE 2. THE COOPERATIVE LABORATORY'S RESEARCH PROGRAM

This agreement applies to research directly or indirectly relating to [**] to be
used as [**] including but not limited to research and development of
procedures, as well as tests and methods related thereto, referred to as the
RESEARCH FIELD hereafter.

Its purpose is to facilitate the activity of the Parties in research and
development for substances and methods that are relevant to the pharmaceutical
industry.

The COOPERATIVE LABORATORY's research program, referred to as the Research
Program hereafter, is defined annually. The initial Research Program is appended
to this agreement

                                                                          Page 3

<PAGE>

(Annex 1). It is updated every year and, if necessary, modified according to the
terms described in Article 5.1.2. In this case, Annex I shall be updated.

ARTICLE 3. MEANS ALLOCATED TO THE COOPERATIVE LABORATORY

3.1 COMPOSITION

The COOPERATIVE LABORATORY is comprised of personnel from the IDENIX
Laboratories, and from the CNRS and the UM II working full-tune or part-time in
the Research Program.

Temporary personnel may be added to the permanent personnel.

The permanent personnel is paid by and supervised by its original organization,
according to the terms described in Article 6.

3.2 LOCATION

The COOPERATIVE LABORATORY is located in premises provided by the UM II, as
described in Annex 2 to this Agreement, which is an integral part of this
Agreement. These premises constitute certain of the resources the UM II is
providing to the COOPERATIVE LABORATORY. Given the renovations done by Idenix
when it moved into the premises, the temporary authorization to use said
premises is given without additional financial cost. When use of the premises
shall cease, and at the latest upon termination of this Agreement, Idenix-shall
return such premises as they then exist.

3.3 MEANS

Each Party promises, for its part, to respect the plan for allocating resources
to the COOPERATIVE LABORATORY as described in Annex 2, which is an integral part
of this Agreement.

This Annex shall be updated every year following discussion between the Parties.

In addition to these planned resources, the Parties will strive to obtain
additional funding from different institutions likely to support the activities
of the COOPERATIVE LABORATORY.

In particular, the Organization will do everything it can to welcome foreign
researchers on long-term assignments with the COOPERATIVE LABORATORY.

ARTICLE 4. PARTNERSHIPS AND SIMILAR AGREEMENTS

Partners from the public or private sectors can be lead to collaborate in the
context of COOPERATIVE LABORATORY activities. Such collaboration will be the
subject of specific research projects signed by all of the Parties, and clauses
related to ownership and exploitation of results must be compatible with those
contained in this agreement. The present agreement shall prevail should there be
inconsistencies between this agreement and these specific contracts.

                                                                          Page 4

<PAGE>

ARTICLE 5. OPERATIONS

The definition and the implementation of the Research Program depend on the
powers of the Steering Committee and of the Director of the COOPERATIVE
LABORATORY, as indicated below.

5.1 STEERING COMMITTEE

5.1.1 COMPOSITION

The Steering Committee of the COOPERATIVE LABORATORY consists of two
representatives from the CNRS, of two representatives of the UM II, and of three
representatives for IDENIX, and of invited members. The Director of the
COOPERATIVE LABORATORY is entitled to participate to the Steering Committee. The
Steering Committee is made up as follows:

For IDENIX:

         -        The Vice President for Europe, IDENIX Laboratory (IDENIX
                  SARL), or his representative.

         -        The Chairman of the Board of Directors of IDENIX, and CEO of
                  IDENIX or his representative.

         -        Mr. Jean-Louis lmbach, Professor Emeritus of the University of
                  Montpellier 11, consultant for IDENIX Laboratories (IDENIX
                  SARL), or his representative.

For the CNRS:

         -        The Director of the Department of Chemistry at the CNRS, or
                  his representative.

         -        The Regional Delegate at the CNRS or his representative.

For UM II:

         -        The President of the Universite Montpellier II, or his
                  representative.

         -        An expert professor at the University Montpellier II,
                  designated by the President of the Universite Montpellier II,
                  or his representative.

In agreement with the other Parties, each Party can invite a person who is
renowned for his/her proficiency in the Research Field to join the Steering
Committee. This person will participate in the Steering Committee's meetings in
an advisory capacity.

Mr. JL lmbach will preside over the Steering Committee.

                                                                          Page 5

<PAGE>

5.1.2 POWERS

The Steering Committee's powers are the following:

-        To determine the orientation of the COOPERATIVE LABORATORY's research
         and to define the annual content of the Research Program or any
         potential changes. To prepare the annual update of Annex 1 described in
         Article 2.

-        To make an annual assessment of the means allocated to the COOPERATIVE
         LABORATORY and to prepare an advanced survey of the resources
         (personnel, financial resources, equipment) necessary for the Research
         Program for the following year.

-        To prepare a progress report on the COOPERATIVE LABORATORY's work and
         examine the results obtained.

-        To make an annual appraisal of the collaboration, and one year before
         the expiration of this Agreement, propose to the Parties its possible
         renewal, in conformity with Article 12 hereafter.

-        To decide matters within its competence related to publications and
         communications, in conformity with Article 8 hereafter.

-        In general terms, to ensure that the activities carried out are in
         compliance with the goals and provisions of this Agreement, and to
         settle important questions related to the smooth operation of the
         COOPERATIVE LABORATORY.

5.1.3 MEETINGS

The Steering Committee will meet at least once a year when notified by its
Chairman, who can also call a meeting at the request of one of the Parties.
Following each meeting, a report is drawn up and sent out to each member of the
Steering Committee.

5.2 DIRECTOR OF THE COOPERATIVE LABORATORY

The Director of the COOPERATIVE LABORATORY is appointed jointly by the Parties.
For the duration of this Agreement, as stipulated in Article 12, the Director is
Mr. Gilles Gosselin.

The Director is responsible for implementing the Research Program and managing
the resources allocated by the Parties to the COOPERATIVE LABORATORY.

He oversees the publication and communications projects involving the
COOPERATIVE LABORATORY's activities and is responsible for obtaining the
Parties' agreement on those projects, as stipulated in Article 8.

He ensures that the personnel involved in the COOPERATIVE LABORATORY's
activities respects the discipline and safety regulations, applicable on the
premises provided by the UM II.

                                                                          Page 6

<PAGE>

ARTICLE 6. PERSONNEL STATUS

The employees from each Patty taking part in the activities of the COOPERATIVE
LABORATORY retain their original status with their employer.

Each Party shall continue to assume all the legal, insurance, social security,
and tax obligations of the employer towards the employees on its payroll, to
ensure their coverage for accidents at work and occupational diseases, and to
apply to than all of the administrative prerogatives of management and staff. To
this end, each Party shall have at its disposal all necessary elements for
assessing its personnel.

Moreover, each Party provides third-party liability insurance for the actions of
its staff in the framework of the COOPERATIVE LABORATORY activities. It is
understood that each employee must comply with the discipline and safety
regulations in force at the UM II, the institution in which the activities of
the COOPERATIVE LABORATORY are carried out.

Personnel of the COOPERATIVE LABORATORY shall be authorized to access the
restaurants and the university library of the UM II. This access constitutes
certain of the resources the UM II is providing to the COOPERATIVE LABORATORY,
as defined in Annex 2 attached hereto.

Use of the shared services of the UM II (such as the common service Physical
Measurements, the reserve of solvents, the Glassworks service, the Fine Organic
Chemistry service [COF], etc.) by the COOPERATIVE LABORATORY shall be invoiced
by the relevant service pursuant to the internal tariff applicable at the date
of the order.

ARTICLE 7. CONFIDENTIALITY

Each Party promises not to publish, nor to use outside of the cooperation
framework, nor to disclose to a third party, in any way whatsoever, any
information which belongs to one or another of the Parties and which it could
have knowledge of as a result of contacts stemming from this Agreement.

Each Party promises to inform its permanent and temporary staff of the terms of
this Article and to ensure that this staff respects them.

This commitment remains effective as long as the information transmitted has not
become part of the public domain, and without any violation of any commitments
resulting from this article, this does not apply to information in cases where
the Party who received this information can prove that it had explicit
permission from the party concerned.

If in order to carry on its mission of creating economic value, one of the
Parties must disclose confidential information to a third party, this can be
done only after written agreement is obtained from the other Parties, specifying
the conditions of disclosure.

The Parties consider that for purposes of this Article 7, Novartis and Novartis
Affiliates shall not be considered as third parties to this Agreement, and shall
be considered as Parties to this Agreement. As a result, each Party shall be
authorized to disclose to Novartis and Novartis Affiliates any information which
belongs to one or another of the Parties, provided the disclosure

                                                                          Page 7

<PAGE>

of this information is materially necessary for Novartis to exercise its rights
under the Development, License and Commercialization Agreement and the Master
Manufacturing and Supply Agreement.

ARTICLE 8. PUBLICATIONS AND COMMUNICATIONS

The publications and communications relating to the COOPERATIVE LABORATORY's
activities are made by mutual agreement between the Parties involved and must
state the contribution made by each Party unless one of the parties explicitly
requests not to be mentioned.

Any reference to the personnel of the COOPERATIVE LABORATORY in articles,
abstracts, speeches or any other form of scientific communication shall contain
the following signature: "COOPERATIVE LABORATORY - IDENIX - University of
Montpellier II - CNRS".

The Director of the COOPERATIVE LABORATORY must obtain the consent of each Party
involved and they must reply within a maximum of [**] after this request. To
that end, each Party will designate a representative within the Steering
Committee responsible for evaluating publication or communications proposals and
for giving his consent in the name of the Party involved.

If no response is received within this time frame, the agreement is considered
to be implicit.

All communications or publications projects can be modified or have information
withheld when disclosure could harm industrial and commercial use of the results
of scientific studies.

In any event, no Party can withhold approval of publication or communication for
more than [**] after the request was made unless it has specified the strategic
nature of this information. In this event, the decision relating to the nature
and duration of the secret is made by the Steering Committee.

The provisions of this Article cannot constitute an obstacle:

-        to the obligation of researchers and teacher-researchers to produce an
         activity report for the organization they are employed by, as this
         communication does not constitute disclosure with respect to industrial
         property laws.

-        nor to presentations of theses of researchers whose scientific activity
         is related to this Agreement.

If necessary, researchers can provide a confidential activity report to the
Comite National de la Recherche Scientifique, to the Chairman of the CNRS
Standing Committee, and also to the President of the University of Montpellier
II. In the same way, theses' presentations can take place behind closed doors.

ARTICLE 9. INDUSTRIAL PROPERTY

                                                                          Page 8

<PAGE>

The CNRS who is responsible for creating economic value out of the work of the
Laboratory is mandated by the UM II to represent the Organization and act in its
name in the context of monitoring the economic value-creation of the COOPERATIVE
LABORATORY's activities.

9.1 RESULTS OBTAINED BY THE COOPERATIVE LABORATORY

Results obtained by the COOPERATIVE LABORATORY, within the framework of research
carried out under this Agreement, are owned jointly by the patties. Results
("Results") include, but are not limited to, technical information, laboratory
notebooks, data, trade secrets, know how, proprietary information and
inventions, documents and materials arising out of such research.

The Parties further agree that any and all rights, title and interest in the
technology, inventions, and/or discoveries directly or indirectly relating to
the subject matter of the patent applications U.S. application numbers [**] and
all continuations, divisionals, continuations-in-part, foreign counterparts, and
all other U.S. and international patent filings that claim priority to these
applications or to which these applications claim priority are deemed to be
included in the results obtained by the COOPERATIVE LABORATORY regardless of
whether the work was carried out prior to the formation of the COOPERATIVE
LABORATORY and regardless of the person or institution that carried out the
work. Such work specifically includes compositions, use and manufacture of [**]
for the treatment of [**]. The rules of co-ownership are defined in Annex 3 and
are an integral part of this Agreement.

9.2 RESULTS OBTAINED OUTSIDE OF THE COOPERATIVE LABORATORY

In the Research Field, as defined in Article 2, each Party retains ownership of
its own research and development activities conducted before the COOPERATIVE
LABORATORY was formed or outside of the Research Program conducted collectively
within the context of this Agreement.

An Owner Party may grant to others the right to use his knowledge at no cost in
order to carry out activities conducted within the context of the COOPERATIVE
LABORATORY.

The parties agree that results obtained outside of the Cooperative Laboratory as
defined in this Section do not include any and all rights, title and interest in
the technology, inventions, and/or discoveries directly or indirectly relating
to the subject matter of the patent applications U.S. application numbers [**]
and all continuations, divisionals, continuations-in-part, foreign counterparts,
and all other U.S. and international patent filings that claim priority to these
applications or to which these applications claim priority, which, by agreement
of Idenix and the Organization, are expressly deemed to fall under Article 9.1
as Results of the Cooperative Laboratory. The Parties further agree that
compositions, use and manufacture of [**] for the treatment of [**] fall under
Article 9.1 and not Article 9.2.

ARTICLE 10. EXPLOITATION OF RESULTS

For the purpose of this article, products and therapeutic procedures for [**]
created in the Research Field are defined and considered as being in the
Exploitation Field.

                                                                          Page 9

<PAGE>

10.1 MANAGING EXPLOITATION

The Parties promise to implement all possible means in order to exploit the
results obtained within the COOPERATIVE LABORATORY framework, whether or not
those results are patent-protected, co-owned, or are the subject of secret
technical files. For this, and subject to the provisions of Article 10.2 below,
they will either exploit them directly, or they will search for partners capable
of moving said results into the industrial stage, and will sign with these new
partners all necessary partnering agreements for licensing options, definitive
licenses or transfer of know-how.

10.2 EXPLOITING COOPERATIVE LABORATORY RESULTS

10.2.1 WITHIN THE EXPLOITATION FIELD

a) IDENIX has the exclusive world-wide right to exploit, directly or indirectly,
the Results obtained in the Exploitation Field within the framework of the
COOPERATIVE LABORATORY, which includes, without limitation, the right to make,
have made, use, sell, offer for sale and import the Results of the COOPERATIVE
LABORATORY in the Exploitation Field, either directly or indirectly, for all
commercial purposes, and the right to enter into license agreements and
collaborations on its own or through its affiliates with third parties to
authorize such third parties to make, use, sell, offer for sale and import said
Results for all commercial purposes, and IDENIX, agrees to pay a royalty to the
Organization under the conditions prescribed in Article 11.

b) IDENIX will ensure management of exploitation results within the Exploitation
Field, as stipulated in Article 10.1.

c) IDENIX is designated by the Organization to represent the Organization and
act in the name of the Organization, as part of the handling of the exploitation
of the Results, including, without limitation, entering into collaboration
and/or license agreements with third parties.

In this framework, IDENIX shall inform the Organization of any exploitation upon
conclusion of any agreement by registered letter with receipt requested.

In addition, in case of exploitation of the Results by a third party, IDENIX
shall transmit a copy of the contractual provisions pertaining to the Results
stipulated in the signed agreements to the Organization within a period not
exceeding four (4) months.

d) In the event that IDENIX foregoes exploiting the results in the context of
co-ownership, it is agreed that the Organization may, following IDENIX's written
consent, exploit those results instead of IDENIX. In this case, the Organization
will pass on to IDENIX a portion of the royalties it will collect, the
proportion to be determined case by case, under the conditions stipulated in a
signed agreement between the Parties.

10.2.2 OUTSIDE THE EXPLOITATION FIELD

Exploitation management as described in Article 10.1, will be ensured by the
Organization outside of the Exploitation Field. The Organization acting by order
of and on behalf of the

                                                                         Page 10

<PAGE>

Parties, will sign agreements with its new collaborators, provided that it has
previously received the written consent of IDENIX with respect to the
collaborator and the terms of the contract. IDENIX will not withhold its consent
without any legitimate motives. In the event of no response two months after the
request, the agreement will be deemed given.

The Organization will pass on to IDENIX a portion of the royalties it will
collect, the proportion to be determined case by case, under the conditions
stipulated in a signed agreement between the Parties.

10.3 EXPLOITATION OF THE LABORATORY RESULTS

10.3.1 WITHIN THE EXPLOITATION FIELD

In the case of results obtained by the Laboratory during this Agreement, outside
of the COOPERATIVE LABORATORY, within the Exploitation Field, IDENIX has
priority evaluation rights, for a period of [**], to consider direct
exploitation of those results. An exploitation agreement stipulating the royalty
conditions will have to be signed by all Owner Parties involved, before any
marketing initiative is made.

The Organization recognizes that the Laboratory does not and shall not be
subject to an agreement which prevents the Laboratory from acting in compliance
with the obligations defined in this Agreement.

10.3.2 OUTSIDE OF THE EXPLOITATION FIELD

In the case of results obtained by the Laboratory outside of the COOPERATIVE
LABORATORY, outside of the Exploitation Field, the Organization is totally free
to exploit the results without having to inform IDENIX of this or to pay IDENIX
any royalties.

ARTICLE 11. ROYALTIES FROM EXPLOITATION OF RESULTS BY IDENIX

In the event of direct or indirect commercial exploitation of the results,
IDENIX promises to pay a royalty to the Organization with a fixed rate of [**]%
on worldwide sales by IDENIX, its subsidiaries and its licensees of products
incorporating the Results, for the duration of this commercial exploitation. The
Parties will sign an agreement specifying the terms of the royalty payments
before any marketing initiative is made.

For purposes of this Article 11, IDENIX subsidiaries shall be defined as any
corporation, company, partnership, joint venture and/or firm that controls, is
controlled by, or is under common control with IDENIX; the notion of "control"
shall mean (a) in the case of corporate entities, direct or indirect ownership
of at least fifty percent (50%) of the stock or shares having the right to vote
for the election of directors, and (b) in the case of noncorporate entities,
direct or indirect ownership of at least fifty percent (50%) of the equity
interest with the power to direct the management and policies of such
non-corporate entities.

ARTICLE 12. DURATION - RENEWAL - CANCELLATION

                                                                         Page 11

<PAGE>

This agreement, which entered into force on the first of January 1999 for an
initial term of four (4) years, was amended and extended for an additional four
year term, to expire on December 31st 2006. Not less than one year before the
expiry of the agreement, the Steering Committee will gather to make an overall
assessment of the results of the collaboration and define the modalities whereby
this collaboration shall continue, in terms of scientific objectives and in
terms of resources. The Steering Committee will communicate its conclusions to
the Parties who will take the decision to stop or continue the collaboration at
the expiry of the term of the Agreement. In the latter case, a new agreement
shall be executed.

One of the Parties is entitled, by right of law, to terminate this Agreement in
the event of non-fulfillment by the other Party of one or more of the
obligations mentioned in this agreement. Termination shall only be effective
three months after the complaining party has sent a registered letter with
acknowledgement of receipt, specifying the reasons for the complaint, unless,
within this time frame, the defaulting party fulfils its obligations or proves
that this was a case of "force majeure".

Termination shall not exempt the defaulting party from fulfilling its
obligations contracted under this agreement prior to the effective time of
termination. In addition, the defaulting party shall be liable for any harm
suffered by the complaining party due to the early termination of this
agreement.

In cast of breach or default by Idenix under this Agreement, Novartis shall be
entitled to remedy such breach or default on behalf of Idenix. To this end, the
Parties shall provide Novartis with a copy of any notice of breach or default
delivered to Idenix, and any related correspondence, at the same time they are
delivered to Idenix.

Novartis shall inform the Parties of its decision to remedy Idenix's breach
within fifteen (15) business days following receipt by Novartis of the notice of
breach served to Idenix. If Novartis elects to remedy Idenix's breach,
termination shall only be effective if Novartis fails to remedy Idenix's breach
within three (3) months as of receipt by Novartis of the notice of breach served
to Idenix.

In the event that Novartis does not exercise its right to remedy such breach or
default on behalf of Idenix, and the other Parties become entitled to terminate
this Agreement as a result of Idenix's failure to remedy its breach, then prior
to the exercise of such right by the Parties, Novartis shall be entitled to
assume all of the rights and obligations of Idenix. The other Parties shall
accordingly notify Novartis in writing of their intention to terminate this
Agreement, and Novartis shall inform such Parties within fifteen (15) business
days as to whether it wishes to assume all the rights and obligations of Idenix
hereunder. If Novartis elects to assume such rights and obligations, it shall be
entitled to an additional fifteen (15) business day period to remedy the breach
or default giving rise to the right to terminate as set forth in this Article
12. Novartis shall succeed Idenix and assume all of Idenix's rights and
obligations hereunder upon, and without the need for any further action by any
Party hereunder other than, Novartis' timely remedy of the breach giving rise to
the termination event as set forth in this paragraph of Article 12.

                                                                         Page 12

<PAGE>

Each Party acknowledges and agrees that as of the date of execution of this
Restated and Amended Cooperative Agreement there is no breach or event of
default existing or continuing by any other Party.

The rights of Novartis provided in Articles 1, 2. 3 and 4.3 of Annex 3 to this
Agreement shall cease in case the Development, License and Commercialization
Agreement is terminated in whole or in part as a result of a breach by Novartis
of its obligations thereunder, or if the Development, License and
Commercialization Agreement is terminated by Novartis for convenience.

Notwithstanding expiration of the agreement, or its earlier termination:

         -        the provisions provided for in the "Confidentiality" article
                  remain in effect for the time periods stipulated in the
                  aforementioned article,

         -        the provisions provided for in the articles "Industrial
                  Propriety", "Exploitation of Results" and "IDENIX Exploitation
                  Royalties" remain in effect.

ARTICLE 13. LITIGATION AND DISPUTES

The Parties shall try to settle out of court all litigation and disputes that
could arise from the interpretation of this Agreement. In the case of persistent
disagreement, the case will be referred to the court of French competent
jurisdiction.

ARTICLE 14. LANGUAGE

This Agreement has been drafted in the English language and in the French
language. In case of contradiction between the two versions, the French version
shall prevail.

ARTICLE 15. COUNTERPART AND FACSIMILE SIGNATURES

Signatures provided by facsimile transmission shall be deemed to be original
signatures.

                                                 Drawn up in Montpellier on:

                                                 ____________________________
                                                 In five original copies
<TABLE>
<S>                           <C>                           <C>
For the Director General of   President of the University   For Idenix SARL and Idenix
the CNRS and on his           Montpellier II                Pharmaceuticals, Inc., The
authority, the Regional                                     Vice President for Europe of
Delegate                                                    Idenix

Michael RETOURNA              Jacques BONNAFE               Jean-Marc ALLAIRE

Novartis Pharma AG
As a limited party to this
Agreement
</TABLE>

                                                                         Page 13

<PAGE>

<TABLE>
<S>                           <C>                           <C>
Subhanu SAXENA, Head,
Business Development and
Licensing - Primary Care

Robert PELZER, General
Counsel
</TABLE>

                                                                         Page 14

<PAGE>

                                    ANNEX 1
                           SCIENTIFIC RESEARCH PROGRAM

The objective of the Scientific Research Program is [**]These new chemical
compounds will have to be tested in order to define their potential activity
against [**].

The research program will consider [**].

Furthermore, there are plans to include in this program [**]There are plans to
[**].

When [**], plans are[**].

In these conditions, and only for the selected compounds, research into
improving [**] will be initiated.

                                                                         Page 15

<PAGE>

                                     ANNEX 2

                     RESOURCES OF THE COOPERATIVE LABORATORY

1 - PERSONNEL

1.1 WORK FORCE

1.1.1 CONTRIBUTION BY THE CNRS:

         -        A part-time Research Director: Dr. G. Gosselin,

         -        A part-time administrative technician: Mrs. MC Bergogne

1.1.2 CONTRIBUTION BY IDENIX

         -        seven Research Engineers and Laboratory Technicians,

         -        eleven laboratory technicians,

         -        two scholarships Doctor Engineer co-financed by the CNRS,

         -        a CIFRE Doctorate student,

         -        a part-time administrative assistant

In total, the contribution of IDENIX, in research personnel, can go up to 20
people.

1.2 PERSONNEL COST BASE

The cost basis for CNRS personnel is determined at the real salary cost, all
taxes included (including Doctoral Student Fellowship ("BDI")) without including
related administration costs.

The costs for University personnel correspond to the costs of the corresponding
categories.

The cost bases for the IDENIX Laboratories personnel are determined based on the
real cost of the employed personnel, including the administrative costs related
to the personnel, whose activity is devoted entirely to implementing the
Research Program.

1.3 FACILITIES

The COOPERATIVE LABORATORY has at its disposal a surface area of at least 200 m
located on the fourth floor of building 17, the chemistry annex and a surface
area of at least 170 m2 located on the ground floor of building 19.

Any modification of the facilities must be negotiated with the UM II, as needed
by the COOPERATIVE LABORATORY and shall be provided in an Annex to this
Agreement.

                                                                         Page 16

<PAGE>

The infrastructure costs of the COOPERATIVE LABORATORY are determined based on
the average cost per square meter of the University research facilities,
evaluated by the University at the time of execution of this Agreement and shall
be updated each year. Those costs are borne entirely by the UM II. In the
context of its contribution to the COOPERATIVE LABORATORY and in consideration
of the renovation work financed by IDENIX).

1.4 SCIENTIFIC EQUIPMENT AND OPERATIONS

The scientific equipment required for carrying out the Research Program will be
[**]The operating costs of the COOPERATIVE LABORATORY (consumable goods, mission
costs) will be [**].

Each year, IDENIX will deliver to the UM II a sum of [**]% of the costs for
consumable goods, to participate in the additional costs generated by the
research.

Schedule of payments:

In December of the current year, payment of a lump sum following assessment of
actual costs.

The applicable VAT rate shall be that in force on the date of payment of the
invoices.

Invoices shall be transmitted in two copies to IDENIX to the attention of Mr.
Jean-Marc Allaire.

The wire payment shall be made upon presentation of the invoice, in the name of
the Accounting Officer of the University of Montpellier II. on the account of
the General Treasury of Herault:

Account N degrees: [**]
Bank code: 10071
Branch code: 34000
Key: 65

                                                                         Page 17

<PAGE>

                                   SPREADSHEET

                 COOPERATIVE LABORATORY: ALLOCATION OF RESOURCES

                             FROM 1999 THROUGH 2002

                                       AND

                             FROM 2003 THROUGH 2006

                                                                         Page 18

<PAGE>

<TABLE>
<CAPTION>
                          1999              2000              2001              2002              Total                  REAL +
                       (in Euros)        (in Euros)        (in Euros)        (in Euros)        (in Euros HT)     REAL    BUDGET
                       ----------  ----  ----------  ----  ----------  ----  ----------  ----  -------------  ---------  -------
   Nature of costs       Budget    REAL    Budget    REAL   Budget     REAL    Budget*   REAL     Budget      1999-2001   2002
--------------------   ----------  ----  ----------  ----  ----------  ----  ----------  ----  -------------  ---------  -------
<S>                    <C>         <C>   <C>         <C>   <C>         <C>   <C>         <C>   <C>            <C>        <C>
           Personnel
                CNRS      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
               UM II      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
              IDENIX      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
          Facilities
  Infrastructure and
   environment costs
             (UM II)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
       Renovation of
reception facilities
             (UM II)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
      Renovation and
     modification to
conform to standards
            (Idenix)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
          Scientific
         environment
  Equipment (Idenix)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
    Consumable goods
            (Idenix)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
    Patents (Idenix)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]
       Mission costs
            (Idenix)      [**]     [**]     [**]     [**]     [**]     [**]     [**]               [**]         [**]      [**]

    Sub-total IDENIX      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]         [**]      [**]
     Sub-total UM II      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]         [**]      [**]
      Sub-total CNRS      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]         [**]      [**]
               TOTAL      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]         [**]      [**]
</TABLE>

Cooperative Laboratory, Allocation of resources    *revision following 3/29/2002

                                                                         Page 19
<PAGE>

<TABLE>
<CAPTION>
                          2003              2004              2005              2006              Total             REAL +
                       (in Euros)        (in Euros)        (in Euros)        (in Euros)        (in Euros HT)        BUDGET
  Nature of costs        Budget*   REAL    Budget*   REAL    Budget*   REAL   Budget*    REAL     Budget      REAL   N+1
-------------------    ----------  ----  ----------  ----  ----------  ----  ----------  ----  -------------  ----  ------
<S>                    <C>         <C>   <C>         <C>   <C>         <C>   <C>         <C>   <C>            <C>   <C>
           Personnel
                CNRS                                                                               [**]
               UM II                                                                               [**]
              IDENIX      [**]              [**]              [**]              [**]               [**]
          Facilities
  Infrastructure and
   environment costs
             (UM II)      [**]              [**]              [**]              [**]               [**]
       Renovation of
reception facilities
             (UM II)                                                                               [**]
      Renovation and
     modification to
conform to standards
            (Idenix)      [**]              [**]              [**]              [**]               [**]
          Scientific
         environment
  Equipment (Idenix)      [**]              [**]              [**]              [**]               [**]
    Consumable goods
            (Idenix)      [**]              [**]              [**]              [**]               [**]
    Patents (Idenix)      [**]              [**]              [**]              [**]               [**]
       Mission costs
            (Idenix)      [**]              [**]              [**]              [**]               [**]

    Sub-total IDENIX      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]       [**]   [**]
     Sub-total UM II      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]       [**]   [**]
      Sub-total CNRS      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]       [**]   [**]
               TOTAL      [**]     [**]     [**]     [**]     [**]     [**]     [**]     [**]      [**]       [**]   [**]
</TABLE>

Cooperative Laboratory, Allocation of resources  *revision following 3/29/2002

                                                                         Page 20
<PAGE>

                                     ANNEX 3

                             CO-OWNERSHIP SETTLEMENT
                        OF COOPERATIVE LABORATORY RESULTS

Any patents covering the Results obtained in the framework of the COOPERATIVE
LABORATORY will be filed in the names of the appropriate parties under the law
of the country of the patent filing, but will be exploited according to the
terms of this contract for the benefit of all of the Parties. Idenix (or
Novartis, as the case may be pursuant to Article 1.1 below) will assume all
costs for submitting a patent, for the patent being granted, for maintaining it,
and for defending it.

IDENIX (or Novartis, as the case may be the case pursuant to Article 1.1 below),
is designated by the Organization to represent the Organization and to act in
its name in all administrative procedures concerning Patents.

The co-ownership shares in patents attributed to each of the Parties will be
determined at the time of the patent's submission and will be based on the
intellectual and financial contributions of the Parties to the invention.

ARTICLE 1. SUBMISSION

1.1 VALUE ENHANCEMENT STRATEGY

During the execution of this agreement, each Party will promptly notify the
other Party in writing of the inventions made in the framework of the
COOPERATIVE LABORATORY.

IDENIX will evaluate the opportunity and the timing for submitting patents
protecting those inventions.

IDENIX will inform the Organization of its decision at the earliest opportunity.
The Parties agree that as may be agreed between Idenix and Novartis, Novartis
shall be entitled to act as Idenix's designee to submit a patent with Novartis
assuming all costs for submitting the patent. When IDENIX or Novartis decide not
to submit a patent, they will specify whether this decision is the result of a
wish to keep the invention secret or of disinterest in it. In the latter case,
the Organization will be able, if it deems this necessary, to proceed with the
submission in the conditions stipulated in Article 3 below.

1.2 SUBMISSION PROCEDURES

IDENIX will provide the Organization with the text of patent requests, and will
keep it informed of developments in the procedure.

The Organization promises to provide IDENIX with all the necessary materials,
technical or administrative, that IDENIX might need for the submission and
approval of patents.

IDENIX will choose the representative responsible for submitting the request and
shall provide such information to the Organization.

                                                                         Page 21

<PAGE>

The Parties promise that the name of the inventors will be mentioned in
agreement with the legal provisions in effect, in the patent requests.

The Parties are committed to ensuring that their employees, mentioned as
inventors, provide all the signatures and accomplish all the formalities
required for submission, approval, enforcement, and protection of the aforesaid
patents, in particular that they sign the assignment of rights in accordance
with the American procedure.

ARTICLE 2. CO-OWNERSHIP EXPLOITATION EXPENSES

IDENIX or Novartis as the case may be pursuant to Article 1.1 above, will cover
all of the administrative costs for patents.

ARTICLE 3. ABANDONMENT OF RIGHTS

If IDENIX or Novartis is not interested in submitting a patent, it will have to
notify, in a timely manner and in writing, the Organization that can then
proceed with the submission in its name and at its expense.

ARTICLE 4. INFRINGEMENT OF PATENT

4.1. The co-owners will inform each other mutually in the shortest time possible
of any instance of infringement of patent by third parties that they are aware
of and/or any claim or patent infringement action brought against them, and will
provide each other with all of the necessary elements at their disposal allowing
them to evaluate the nature and the impact of such.

4.2. If one of the Parties estimates that the observed infringement could
significantly impact the exploitation of one or more patents, it can consult the
other Party to discuss the most appropriate measures to end the infringement.

4.3. The Parties hereby grant IDENIX the first, full and sole right to enforce
or defend any patent obtained covering Results at IDENIX' sole expense, and the
Organization agrees to cooperate, assist, and participate in any litigation that
IDENIX deems necessary or desirable to defend such patents. In addition, the
Parties agree that as may be agreed between Idenix and Novartis, Novartis shall
be entitled to act as Idenix's designee to exercise Idenix's first right to
enforce or defend any patent obtained covering the Results with the costs of,
and any amount recovered or owed resulting from, any enforcement or defense
action or proceeding to be allocated between Novartis and IDENIX in accordance
with the Development, License and Commercialization Agreement. If IDENIX or
Novartis elects in writing not to defend or enforce a patent being infringed,
then the Organization is granted the second, full and sole right to enforce or
defend any patent obtained covering Results at the Organization's sole expense,
and then IDENIX agrees to cooperate, assist, and participate in any litigation
that the Organization deems necessary or desirable to defend such patents.

4.4. Subject to the provisions of Section 4.3 of this Article 4 above, any
damages awarded to the Parties by the courts will be shared between the Parties
in proportion to their participation in external expenses incurred to prosecute
the action successfully.

                                                                         Page 22

<PAGE>

4.5. If the Organization does not want to exercise the second right to enforce
the patent, either CNRS or UM II may individually take legal action at its own
expense, wherein IDENIX and the other party agree to cooperate, assist and
participate in any such litigation. In this case, all damages will be awarded to
the litigating party in full.

4.6. The Parties make a mutual commitment to provide all documents, powers, and
signatures to each other that they might need to undertake the legal actions in
accordance with the stipulations contained in all of the provisions of this
Article 4.

4.7. Subject to the provisions of Section 4.3 of this Article 4 above, if any
patent infringement actions were brought against one of the Parties for using
co-ownership Results, based on use of patents and/or of know-how obtained in the
framework of the COOPERATIVE LABORATORY, the other Parties will communicate
information they have for its defense. If the accused Party is condemned
following a patent infringement action, it will not implicate the other Parties.
In particular, it will refrain from calling another party in warranty
[impleading] and will not request any indemnity, nor refund of sums of any kind
already delivered to that party, nor any reduction in sums still owed at the
time of the final legal decision.

ARTICLE 5. ASSIGNMENT OF RIGHTS

Each co-owner can dispose of all or part of its co-ownership rights for patents
or patent requests and the corresponding secret technical files. The third Party
assignee will then be subrogated to the assignor in all rights and obligations
resulting from co-ownership of the securities under consideration.

Prior to any partial or total assignment of a co-ownership right, the assignor
Party must notify the other co-proprietor of its intention to assign its rights
in a registered letter mailed to the other co-owner, naming the potential third
Party assignee, and specifying the financial conditions of the assignment. In
this case, the other co-owners will benefit by virtue of a preemptive right to
financial conditions at least equal to those consented to the third Party. This
preemptive right will stand for a period of two months following notification.
At the end of this time, the assignor Party will benefit from the assignment
authorization automatically.

The right of notice and preemption prior to an assignment of patent or technical
rights does not apply in the case of the sale of all or substantially all of the
assets of the party, in which case the co-ownership right flows automatically
with the asset sale to the new owner of the assets. The new owner of all or
substantially all of the assets of the prior co owner must confirm in writing
its agreement to the co-ownership provisions set forth in this Agreement.

Provided the third Party assignee has confirmed previously in a registered
letter with acknowledgement of receipt, addressed to the co-owner who is not
assigning rights, his total support for the contents of the current co-ownership
regulations, the assignee will be subrogated by right of law to the assignor in
the rights and obligations provided for in the aforementioned regulations.

CNRS warrants and represents that it is the sole owner of all inventions,
conceptions, trade secrets, technical developments and patents of Dr. Gilles
Gosselin carried out or accomplished in

                                                                         Page 23

<PAGE>

the course of Dr. Gosselin's research and Results in the Cooperative
Laboratory. CNRS has not granted any rights held by the Cooperative Laboratory
to any other entity, and no government entity or other entity holds such rights
other than CNRS.

UM II warrants and represents that it is the sole owner of all inventions,
conceptions, trade secrets, technical developments and patents of Dr. Jean-Louis
Imbach carried out or accomplished in the course of Dr. Imbach's research and
Results in the Cooperative Laboratory. UM II has not granted any rights held by
the Cooperative Laboratory to any other entity, and no government entity holds
such rights other than UM II.

ARTICLE 6. DURATION OF CO-OWNERSHIP

All of these provisions will apply as long as the last intellectual property
rights subjected to co-ownership remain in force.

                                                                         Page 24

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00059-of-00352.parquet"}]]